Haleon (NYSE:HLN) Releases Earnings Results

Haleon (NYSE:HLN) posted its quarterly earnings results on Thursday. The company reported $0.05 EPS for the quarter, Zacks reports. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion.

Haleon Trading Up 3.9 %

Shares of NYSE HLN opened at $10.18 on Friday. The business has a 50-day moving average price of $9.59 and a two-hundred day moving average price of $9.83. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $46.06 billion, a PE ratio of 29.93, a PEG ratio of 2.82 and a beta of 0.28. Haleon has a one year low of $7.89 and a one year high of $10.80.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Haleon currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.